Last January, Sanofi (SNY) disclosed that the U.S. Attorney in Boston sent a subpoena seeking documents about its efforts to promote the use of two multiple sclerosis drugs. Specifically, the federal officials wanted to know about relationships with patient charities, patient assistance programs, and sales and marketing activities for the two medicines, Aubagio and Lemtrada.
At the time, the subpoena garnered little attention because a growing number of drug makers have been asked to provide this sort of information. And like other companies, Sanofi noted it was cooperating with the investigation. But an internal company document that a Sanofi lawyer sent to employees offers a rare glimpse into the issues now preoccupying the pharmaceutical industry.
About the Author Reprints
